Eiki Ichihara
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Eiki Ichihara has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Hiroshige Yoshioka
Department of Respiratory Medicine, Kurashiki Central Hospital, 1-1-1 Miwa, Kurashiki, 710-8602, Japan
1 shared publication - Isao Oze
Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Japan
1 shared publication Junji Matsuoka
1 shared publication- Katsuyuki Hotta
Center for Innovative Clinical Medicine, Okayama University Hospital, Okayama, Japan
1 shared publication Katsuyuki Kiura
1 shared publication- Katsuyuki Kiura
Department of Respiratory Medicine, Okayama University Hospital, Okayama, Japan
1 shared publication
Latest Publications
- 2 December 2010
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 363 (23) , 2263-2265
Early Palliative Care in Non–Small-Cell Lung Cancer
The surprising and encouraging study by Temel and colleagues (Aug. 19 issue)1 suggests that the early introduction of palliative care prolongs survival among patients with metastatic non-small-cell lung cancer. However, two essential points regarding patient demographic characteristics were not reported. First, there were no data regarding the regimens and number of chemotherapy cycles in each group. Could the patients assigned to early palliative care undergo more chemotherapy? Second, the authors did not describe whether the patients assigned to early palliative care, as compared with the patients assigned to standard care, had better performance status after intervention. The use of chemotherapy and performance status are inextricably linked with survival in metastatic non–small-cell lung cancer.2,3 We would like to know whether the early palliative care itself resulted in longer survival through improvements in the quality of life and mood or whether the better performance status restored with early palliative care made it possible to receive additional chemotherapy at an appropriate time that might confer a survival benefit.
- 2 December 2010
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 363 (23) , 2263-2265
Early Palliative Care in Non–Small-Cell Lung Cancer
The surprising and encouraging study by Temel and colleagues (Aug. 19 issue)1 suggests that the early introduction of palliative care prolongs survival among patients with metastatic non-small-cell lung cancer. However, two essential points regarding patient demographic characteristics were not reported. First, there were no data regarding the regimens and number of chemotherapy cycles in each group. Could the patients assigned to early palliative care undergo more chemotherapy? Second, the authors did not describe whether the patients assigned to early palliative care, as compared with the patients assigned to standard care, had better performance status after intervention. The use of chemotherapy and performance status are inextricably linked with survival in metastatic non–small-cell lung cancer.2,3 We would like to know whether the early palliative care itself resulted in longer survival through improvements in the quality of life and mood or whether the better performance status restored with early palliative care made it possible to receive additional chemotherapy at an appropriate time that might confer a survival benefit.